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Cerebral aneurysms are common vascular lesions. Little is known about the pathogen-
esis of these lesions and the process by which they destabilize and progress to rupture. 
Treatment decisions are motivated by a desire to prevent rupture and the devastating mor-
bidity and mortality associated with resulting subarachnoid hemorrhage (SAH). For patients 
presenting with SAH, urgent intervention is required to stabilize the lesion and prevent 
re-rupture. Those patients fortunate enough to survive a presenting SAH and subsequent 
securing of their aneurysm must still face a spectrum of secondary sequelae, which can 
include cerebral vasospasm, delayed ischemia, seizures, cerebral edema, hydrocephalus, 
and endocrinologic and catecholamine-induced systemic dysfunction in cardiac, pul-
monary, and renal systems. Increased focus on understanding the pathophysiology and 
molecular characteristics of these secondary processes will enable the development of 
targeted therapeutics and novel diagnostics for improved patient selection in personalized 
medicine trials for SAH. In unruptured cerebral aneurysms, treatment decisions are less 
clear and currently based solely on treating larger lesions, using rigid aneurysm size cut-
offs generalized from recent studies that are the subject of ongoing controversy. Further 
compounding this controversy is the fact that the vast majority of aneurysms that come to 
clinical attention at the time of a hemorrhagic presentation are of smaller size, suggesting 
that small aneurysms are indeed not benign lesions. As such, patient-specific biomark-
ers that better predict which aneurysms represent high-risk lesions that warrant clinical 
intervention are of vital importance. Recent advancements in genomic and proteomic 
technologies have enabled the identification of molecular characteristics that may prove 
useful in tracking aneurysm growth and progression and identifying targets for prophylactic 
therapeutic interventions. Novel quantitative neuroimaging technologies have also recently 
emerged, capable of non-invasive characterization of hemodynamic factors, inflammation, 
and structural changes in aneurysmal walls. The combined use of these quantitative 
neuroimaging and molecular-based approaches, called Radiogenomics, is a technique 
that holds great promise in better characterizing individual aneurysms. In the near future, 
these radiogenomic techniques may help improve quality of life and patient outcomes 
via patient-specific approaches to the treatment of unruptured cerebral aneurysms and 
personalized medical management of secondary processes following aneurysmal SAH.
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inTRODUCTiOn
Cerebral aneurysms are common vascular lesions with preva-
lence in autopsy studies as high as 5% (1). The most common 
clinical presentation of cerebral aneurysms is rupture leading to 
subarachnoid hemorrhage (SAH) (2). The estimated incidence of 
SAH from ruptured intracranial aneurysms in the United States 
is one case per 10,000 persons (2, 3). An estimated 10% of these 
patients die before reaching medical attention with the 30-day 
mortality rate reaching as high as 45%. The 30% of patients who 
do survive suffer significant disability (3–5).
Aneurysms that present with SAH represent unstable lesions 
with significant risk of re-rupture, with recurrent hemorrhage 
within the first 24 h in as many as 4%, and in as many as 20% 
within the first 2 weeks of the initial event, if left unsecure (2). 
Symptomatic unruptured aneurysms presenting with new cranial 
nerve palsies or brainstem dysfunction are at increased risk of 
rupture, as high as 6% per year, and should be treated (6).
Recent advances in genomic and proteomic technologies 
have enabled the identification of molecular characteristics that 
may prove useful in tracking aneurysm growth and progression 
to guide treatment of unruptured aneurysms. Novel quantita-
tive neuroimaging technologies have also recently emerged, 
capable of non-invasive characterization of hemodynamic 
factors, inflammation, and structural changes in aneurysmal 
walls. The combined use of these quantitative neuroimaging 
and molecular-based approaches, called Radiogenomics, is a 
technique that holds great promise in better characterizing 
individual aneurysms.
Beyond securing the aneurysm from risk of rupture, the 
treatment of patients with aneurysmal SAH includes managing 
a significant spectrum of secondary sequelae, which can include 
cerebral vasospasm (CV), delayed ischemia, seizures, cerebral 
edema, hydrocephalus, and endocrinologic and catecholamine-
induced systemic dysfunction in cardiac, pulmonary, and renal 
systems. Optimizing management of these complex multisystem 
factors is critical for improving the 30-day mortality rate (as high 
as 45%) and the proportion of significantly disabled survivors (as 
high as 30%). An increased focus on understanding the patho-
physiology and molecular characteristics of these secondary 
processes will enable the development of targeted therapeutics 
and novel diagnostics for improved patient selection in personal-
ized medicine trials for SAH.
CURRenT COnTROveRSieS in THe 
MAnAGeMenT OF CeReBRAL 
AneURYSMS
The management of asymptomatic unruptured aneurysms is 
the subject of ongoing controversy. A recent prospective obser-
vational cohort study, The International Study of Unruptured 
Intracranial Aneurysms (ISUIA), in which 1,692 patients were 
preselected to be conservatively followed, reported that the 
subgroup with the smallest aneurysms (defined in this study as 
<7 mm) had an observed 5-year rupture rate of 0% during the 
interval they were followed (1). Controversy surrounding the 
methodology of this study exists because, unlike a true natural 
history study, patients may have been preselected for inclusion 
on the basis of their surgeons’ opinions that these aneurysms 
were less likely to rupture. Consistent with this, the rupture 
rates of this observational cohort were significantly lower than 
in other studies of unruptured cerebral aneurysms (2, 7–10). 
Another controversy was the ISUIA-reported risk of morbidity 
associated with microsurgical clipping of unruptured aneurysms 
as 15.7% after 1  year, which raised significant concerns when 
compared to the literature reporting surgical morbidity in the 
range of 3–7% (2). The result of inappropriately generalizing the 
ISUIA data of a preselected subset of aneurysms has nonetheless 
had the important effect of at least temporarily discouraging the 
treatment of many unruptured cerebral aneurysms. The result 
this will have on actual patient outcomes in real-world popula-
tions remains to be seen. In the interim, it is vitally important 
to generate improved biomarkers that move past arbitrary size 
cutoffs so that clinicians can better characterize rupture risk in 
individual lesions and thus improve decision-making for each 
unique patient.
Moving beyond the question of when to intervene, the issue 
of how to intervene is also the subject of much controversy, 
with options including microsurgical clipping and endovas-
cular coiling. The International Subarachnoid Aneurysm Trial 
(ISAT) reported prospectively randomizing 2,143 patients, who 
presented with ruptured aneurysms, to either clipping or coil-
ing (11). an important caveat of this analysis is that these 2,143 
patients represented only a fraction of the total 9,559 patients the 
study initially assessed with aneurysmal SAH. The vast majority 
of real-world aneurysmal SAH patients (77.6%) were excluded 
upfront from this analysis, based on inclusion criteria that 
resulted in an analysis of a minority of aneurysmal SAH patients. 
The clinical characteristics of the resulting study demonstrated 
the profound effects of this selection bias, including 90% having 
favorable clinical grade, 95% having aneurysms in the anterior 
circulation, and 90% of aneurysms being <10 mm. Generalizing 
these findings may be inappropriate, and in fact many con-
tributors to the ISAT trial have themselves pointed out significant 
issues with data transparency and need for secondary sources 
of data on this critical topic (12). As a result of these significant 
limitations of ISUIA and ISAT, and despite the impact they have 
already had on current treatments, whether to observe, surgically 
treat, or endovascularly manage intracranial aneurysms remains 
controversial.
Whether the increased durability of clipping outweighs its 
slightly higher risks compared to coiling is unknown. In fact, 
even ISAT investigators reported that the rehemorrhage rates 
and recoiling rates in subsequent analyses of their data indicate 
significant problems with the study’s original conclusions (12). 
Nevertheless, endovascular technology is likely to continue to 
advance with indications and outcomes likely to be constantly 
changing.
As such, patient-specific biomarkers that better predict which 
aneurysms represent high-risk lesions and which lesions are likely 
to respond best to a particular therapy are of vital importance.
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eMeRGinG BiOMARKeRS in THe 
MAnAGeMenT OF UnRUPTUReD 
CeReBRAL AneURYSMS
Although the pathogenesis of cerebral aneurysms is unknown, 
their development at stereotyped locations associated with 
specific hemodynamic factors suggests that regional blood 
flow patterns play a fundamental role in the pathophysiology 
of the disease (13–16), as recently reviewed by Can and Du 
(17). Using non-invasive quantitative imaging to characterize 
aneurysm morphology and computational fluid dynamics 
analyses of resulting hemodynamics, these studies have pro-
vided new insight into the key factors that play in a role in 
aneurysm progression and risk of rupture. Interestingly, bifur-
cation aneurysms were associated with high wall shear stress 
(WSS), suggesting that wall remodeling and degeneration via 
endothelial injury is of greatest relevance in these aneurysms. 
In contrast, sidewall aneurysms were associated with low WSS, 
suggesting that stasis of blood flow, and resulting endothelial 
dysfunction with pro-inflammatory-mediated degeneration of 
the aneurysm wall, may be more clinically relevant in these 
aneurysms (17). In paired analysis of unruptured aneurysms 
that went on to rupture, the hemodynamic factors associ-
ated with rupture risk included low shear index area (LSA), 
defined as the area of the aneurysm wall exposed to a WSS 
<10% of the mean parent vessel, which was observed to be 
higher in aneurysms that went on to rupture (i.e., a greater 
percentage of the aneurysm wall was exposed to low shear 
stresses). However, patients with ruptured aneurysms expe-
rienced a higher maximum WSS (17). Taken together, these 
data suggest that a significant area of low shear stress results in 
endothelial dysfunction and degeneration of the aneurysmal 
wall to the point of susceptibility, and that focally high WSS 
exerted against this background results in the subsequent 
rupture event. These hemodynamic parameters of LSA and 
WSS provide a more dynamic measure of the aneurysm than 
arbitrary size measurement cutoffs proposed by the ISUIA and 
ISAT studies, and these next generation parameters will likely 
play an increasing role in the patient-specific characterization 
of aneurysms and associated clinical decision-making in the 
future.
Recently, ferumoxytol-enhanced magnetic resonance imaging 
has shown promise in non-invasively characterizing aneurysm 
inflammation. Increased ferumoxytol uptake in aneurysm walls 
is a measure of myeloid cell inflammation, and has predicted 
aneurysm instability and an increased 6-month rupture risk in 
pilot studies. Thus, increased ferumoxytol uptake may serve as 
a biomarker for lesions warranting urgent intervention (18–20). 
As hemodynamic factors, such as high LSA, may result in a 
pro-inflammatory milieu, with subsequent endothelial apop-
tosis and aneurysmal wall degeneration (17), a combination 
of hemodynamic and inflammatory characterization by newer 
non-invasive neuroimaging modalities may become increasingly 
important in the patient-specific management of aneurysms in 
the near future.
eMeRGinG BiOMARKeRS in THe 
MAnAGeMenT OF SeCOnDARY 
SeQUeLAe OF SAH
Secondary sequelae of SAH include CV, delayed ischemia, 
seizures, cerebral edema, hydrocephalus, and endocrinologic 
and catecholamine-induced systemic dysfunction in cardiac, 
pulmonary, and renal systems. Currently there are no established 
biomarkers for preclinical diagnosis or monitoring of progression 
of these secondary sequelae.
Hydrocephalus can develop in up to 20% of patients who have 
aneurysmal SAH (2), requiring ventriculostomy for drainage 
of cerebrospinal fluid (CSF). There are currently no accurate 
predictors of shunt dependency after ventriculostomy placement 
in SAH, but emerging CSF-based biomarkers that reflect the rate 
of CSF clearance, as well as neuroimaging that quantifies CSF 
dynamics, hold promise in selecting patients for rapid removal of 
the external ventricular drain to minimize risks of ventriculitis.
Cerebral vasospasm is a major cause of morbidity and mortal-
ity in SAH and refers to intracranial vasoconstriction that may 
occur between 3 and 14  days after SAH. The pathogenesis of 
vasospasm is unknown and even with maximal therapy vasos-
pasm can cause strokes and death (21). Approximately two-thirds 
of all patients with SAH who undergo cerebral angiography 
will demonstrate radiographic evidence of vasospasm, known 
as angiographic CV. Symptomatic (clinical) CV, defined as the 
development of new focal neurologic deficits in patients with 
SAH in association with angiographic CV and not attributable 
to other causes, occurs in approximately one-third of all patients 
with SAH. Approximately one-third of these patients with CV 
die from the CV-related infarcts and another one-third are left 
significantly disabled. Medical treatment of CV consists of orally 
administered nimodipine (60 mg every 4 h for 21 days), which 
has been shown to improve outcome after SAH (22). Patients 
are monitored with daily transcranial Doppler (TCD) velocities, 
and in patients who develop elevated TCDs and new neurologic 
deficits, triple-H therapy is initiated (hypertension, hypervolemia, 
and hemodilution) (3). Patients with persisting neurologic deficit 
undergo urgent catheter angiography to confirm the presence 
of vasospasm and if confirmed are treated with intra-arterial 
administration of smooth muscle relaxants, such as papaverine 
or nicardipine or with balloon angioplasty. These antispasmodic 
therapies can result in angiographically confirmed arterial dilata-
tion in >90% of patients (23–25).
Multiple CSF biomarkers have been identified for the early 
diagnosis of symptomatic CV, as recently reviewed by Lad et al. 
(26), which may help guide patient-specific selection for person-
alized medicine trials aimed at preventing delayed ischemic neu-
rologic deficits, such as protocols using earlier angiography for 
early intra-arterial smooth muscle relaxant therapy. Endothelin-1 
has been shown to significantly increase days 4–7 after SAH in 
patients who develop symptomatic CV versus those who do not 
(27), and this increase predicts the occurrence of symptomatic 
CV (28). CSF interleukin (IL)-6 levels also significantly increase 
in the first 4–5  days after disease onset in patients with CV 
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compared to those with uncomplicated SAH (29). These data 
suggest that endothelin-1 and IL-6 could be useful diagnostic 
and predictive markers for CV and potentially useful tools for 
personalized medicine protocols in the treatment and prevention 
of symptomatic CV.
Subarachnoid hemorrhage can result in overactivity of the 
sympathetic nervous system and catecholamine surge with result-
ing multisystem dysfunction. Cardiac abnormalities after SAH 
are common, including electrocardiographic changes, elevations 
in cardiac enzymes, and left ventricular dysfunction in up to 
one-third of cases (30–32). These abnormalities appear to directly 
result from the excessive catecholamine release in response to the 
intracranial hemorrhage (33). In some patients, other adverse 
events from this catecholamine surge include pulmonary edema, 
hypotension requiring vasopressors, delayed strokes, and death 
(34). The combination of decreased cardiac contractility, increased 
pulmonary vascular permeability, increased pulmonary vascular 
pressure, and increased volume from resuscitation results in the 
development of this pulmonary edema, and increased preload 
results in stretching of the cardiac atrium and atrial natriuretic 
peptide release (peaks on day 2) (35). This natriuretic peptide acts 
on renal tubules, triggering sodium and volume loss, and without 
appropriate resuscitation, plasma sodium levels fall significantly 
by post-rupture days 4–6, which can be preempted by judicious 
volume and salt replacement. This has been shown to reduce the 
incidence of severe CV (36). The relationship between natriuretic 
and diuretic states after aneurysmal SAH and the subsequent 
development of CV, particularly with regards to activation of 
the renin–angiotensin–aldosterone system between days 4 and 
6, warrant further study and may provide further biomarkers to 
guide patient-specific treatments that optimize sodium and fluid 
balance, address natriuretic and renin–angiotensin–aldosterone 
signaling dysfunction, and provide appropriate inotropic and 
vasopressor support during myocardial dysfunction and ventila-
tor support during neurogenic pulmonary edema.
COnCLUSiOn
Patient-specific biomarkers that better predict which cerebral 
aneurysms represent high-risk lesions worthy of intervention 
are of vital importance. Personalized treatment strategies are also 
increasingly important in the management of secondary sequelae 
from SAH, including CV, delayed ischemia, seizures, cerebral 
edema, hydrocephalus, and endocrinologic and catecholamine-
induced systemic dysfunction in cardiac, pulmonary, and renal 
systems. The combined use of these quantitative neuroimaging 
and molecular-based approaches, called Radiogenomics, is a 
technique that holds great promise in better characterizing 
individual aneurysms. In the near future, these radiogenomic 
techniques may help improve quality of life and patient outcomes 
via patient-specific approaches to the treatment of unruptured 
cerebral aneurysms and personalized medical management of 
secondary processes following aneurysmal SAH.
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